ESC Premium Access

PCSK9 inhibitors associated hyperglycemic disorders: a real world, pharmacovigilance study

Congress Presentation

About the speaker

Doctor Adam Goldman

Chaim Sheba Medical Center, Tel Hashomer (Israel)
0 follower

17 more presentations in this session

Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients with atrial fibrillation on direct-acting oral anticoagulants

Speaker: Mr A. Holt (Copenhagen, DK)

Thumbnail

Usage and risk with phosphodiesterase type 5 inhibitors in male patients with chronic ischemic heart disease on oral organic nitrates

Speaker: Mr A. Holt (Copenhagen, DK)

Thumbnail

PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual kinetic mechanism of action

Speaker: Mr Q. Ying (Perth, AU)

Thumbnail

Antifibrotic and anti-inflammatory effects of the selective nonsteroidal MR antagonist finerenone in preclinical pulmonary fibrosis

Speaker: Doctor M. Delbeck (Wuppertal, DE)

Thumbnail

Aspirin vs. P2Y12 inhibitors with anticoagulation therapy for atrial fibrillation: insights from the AFIRE trial

Speaker: Assistant Professor H. Fukaya (Sagamihara, JP)

Thumbnail

Access the full session

Congress committee e-posters choice in pharmacology and pharmacotherapy

Speakers: Doctor A. Goldman, Mr A. Holt, Mr A. Holt, Mr Q. Ying, Doctor M. Delbeck...
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

Lipoprotein(a): an emerging lipid risk factor – discussion.

27 August 2021

ESC Premium Access

Future treatments for lipoprotein(a).

27 August 2021

ESC Premium Access

Current treatment for elevated lipoprotein(a).

27 August 2021

ESC 365 is supported by

logo Novo Nordisk